Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled Trial.
Icotrokinra, an oral peptide targeting moderate-to-severe plaque psoriasis, just wrapped up a year-long clinical trial in teenagers. The ICONIC-LEAD study tracked both clinical metrics and how patients actually felt about their skin. The results? Consistent gains on both fronts — and those gains stuck around for the full twelve months.
J Am Acad Dermatol
by Soung J, Lebwohl MG, Hebert A et al.
“Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled Trial. Soung J(1), Lebwohl MG(2), Hebert A(3), Pink AE(4), Shi Y(5), Hong HC(6), Iaconangelo C(7), Miller-Kassamali M(8), Cafone J(8), DeKlotz CMC(8), Jiang J(8), Li S(8), Yang YW(8), Eichenfield L(9). Author information: (1)Southern California Clinical Research, Santa Ana and Harbor University of California Los Angeles, CA, USA. Electronic address: doctorsoung@gmail.com. (2)Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. (3)UTHealth McGovern Medical School, Houston, TX, USA. (4)St. John's Institute of Dermatology, Guy's & St. Thomas' NHS Foundation Trust and King's College London, London, UK. (5)Shanghai Disease Hospital, Tongji University School of Medicine, Shanghai, China; Institute of Psoriasis at Tongji, University School of Medicine, Shanghai, China. (6)University of British Columbia, Department of Dermatology and Skin Science, Vancouver, BC, Canada; Dr. Chih-ho Hong Medical Inc., a member of Probity Medical Research, Surrey, BC, Canada. (7)Johnson & Johnson, Horsham, PA, USA. (8)Johnson & Johnson, Spring House/Horsham, PA, USA. (9)Department of Dermatology, Pediatric and Adolescent Dermatology, University of California, San Diego School of Medicine, San Diego, USA; Rady Children's Hospital, San Diego, USA.”
This is a big deal for peptide research. Most current psoriasis treatments for adolescents involve injectables or biologics. Icotrokinra stands out as a targeted peptide that you swallow — not inject — and it’s built to address the overactive immune signaling behind plaque psoriasis. The trial included teens from North America, Europe, and Asia, adding valuable diversity to the data.
Key takeaway:
Participants saw meaningful improvements in their visible symptoms, measured by standard clinical psoriasis scores
Patient-reported outcomes tracked the same path — less itch, less embarrassment, and real quality-of-life gains
The benefit held up for a year, which is rare for oral options in this population
This isn’t just good news for people studying psoriasis. It’s a strong proof-of-concept for oral peptide therapeutics in chronic inflammatory conditions. If a targeted peptide like icotrokinra can show durable effects in a tough crowd (teenagers, with severe disease, over a long haul), it opens the door for similar strategies across dermatology and beyond.
The ICONIC-LEAD trial pushes the envelope on what peptides can do as oral agents, not just injectables. For anyone building the next generation of peptide-based therapies, this is essential reading. Dive deeper into the science and see what other projects are in the pipeline at our peptide research index.
Oral peptides are having a moment — and it’s more than hype.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.